Yena Lee
Research staff member in the Mood Disorders Psychopharmacology Unit, University Health Network / University of Toronto
Data updated
Papers
Trials
Research Footprint
Yena Lee appears in 6 tracked papers (2020–2022), most studied alongside Ketamine, Esketamine and Psilocybin, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Anxiety Disorders.
Most-cited paper: Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation (676 citations).
Frequent co-authors: Roger McIntyre, Jonathan Rosenblat and Roger Ho.
Background & Research
Yena Lee appears in the Mood Disorders Psychopharmacology Unit at University Health Network in Toronto and has coauthored several papers on ketamine, sleep, suicidality, and treatment-resistant depression. Her publication record also includes a broad expert opinion on ketamine/esketamine and a review of psilocybin and MDMA in mental illness, indicating work at the intersection of translational psychiatry and psychedelic medicine.
Key Impact
Yena Lee is a co-author on multiple influential ketamine and psychedelic psychiatry papers, including reviews and real-world studies on treatment-resistant depression and a narrative review of psilocybin and MDMA.
Collaboration Network
24 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Yena Lee is associated with.
University of Toronto
University of Toronto is a leading Canadian research university whose psychedelic and psychiatric research spans the Department of Psychiatry, University Health Network collaborations, and specialized clinical units including mood-disorders psychopharmacology programs.
View stakeholder →Brain and Cognition Discovery Foundation
Non-ProfitCanada-based foundation backing translational and clinical research programs in mental health, including psychedelic-relevant workstreams.
View stakeholder →University Health Network, Toronto
Toronto's largest research hospital network and home to the Nikean Psychedelic Psychotherapy Research Centre — Canada's first dedicated psychedelic research centre, funded by a $5 million donation. Led by Dr. Emma Hapke, UHN's centre conducts psilocybin-assisted therapy trials for cancer patients and body dysmorphic disorder, alongside MDMA research for PTSD.
View stakeholder →